Mr. Clark, at the last meeting, we heard an example of a drug, for a rare disease, called Cystagon. People were paying $15,000 a year and it was under that special access program. The company didn't apply to be licensed for that. They applied to be licensed for Procysbi, which cost $350,000 per year. It's the same drug and the same molecule, except that there's a coding that's different, so the release is different.
Is it time for us to consider some form of compulsory licensing or at least address that? When we have a company that is foisting on to the public the same drug that costs many times more than another drug that we know is available, that tells me that something is wrong with the system.
What's your fix to that?